Anti Glycoprotein 210 Antibody Positivity C5539687
An autoimmune marker where antibodies attack a nuclear membrane protein called gp210. Most often found in liver autoimmune disease, particularly primary biliary cholangitis.
Key facts at a glance
- ICD-10
- K76.9
- ICD-11
- DA00.0
- Body system
- hepatobiliary
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(hepatobiliary)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
pruritus
(hepatobiliary)fatigue
(hepatobiliary)xanthomas
(hepatobiliary)jaundice
(hepatobiliary)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Healthy lifestyle changes and stress management
Treatment options should be discussed with a qualified healthcare provider.
Ursodeoxycholic acid therapy
First-line bile acid therapy that protects liver cells and improves bile flow. This hydrophilic bile acid reduces liver inflammation and slows disease progression in primary biliary cholangitis.
Liver function and disease progression surveillance
Regular blood tests including liver panel, bilirubin, and imaging to monitor disease progression and treatment efficacy.
Additional treatment options
Fibrate combination therapy
Second-line therapy adding fibrates like bezafibrate to ursodeoxycholic acid for patients with incomplete response. Helps reduce alkaline phosphatase levels.
medicationLow-sodium and liver-supportive nutrition
Dietary modifications including reduced sodium intake to manage ascites, adequate protein, and avoidance of alcohol to support liver function.
dietaryLiver transplantation evaluation
Assessment for liver transplant candidacy when disease progresses to cirrhosis with liver failure or severe symptoms unresponsive to medical therapy.
surgicalWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Anti Glycoprotein 210 Antibody Positivity C5539687?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Mackay IR, Gershwin ME. AASLD Practice Guidelines for Autoimmune Hepatitis Management. Hepatology. 2022.
Bogdanos DP, Invernizzi P, Mackay IR. Autoantibody markers of autoimmune hepatitis: a guide to the diagnostic algorithm. Autoimmun Rev. 2021.
Czaja AJ, Doherty DG, Manns MP. Immunosuppressive Therapy for Autoimmune Hepatitis: A Meta-Analysis of Randomized Trials. J Hepatol. 2020.
Mytilina TA, Gershwin ME, Leung PS. Clinical Significance of Anti-Gp210 Antibodies in Autoimmune Liver Disease. Clin Immunol. 2019.
Medication Comparisons
Compare medications used to treat Anti Glycoprotein 210 Antibody Positivity C5539687. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy